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APC geneColorectal cancer (CRC) represents one of the most prevalent and lethal malignant neoplasms and every individ-
ual of age 50 and above should undergo regular CRC screening. Currently, themost effective preventive screening
procedure to detect adenomatous polyps, the precursors to CRC, is colonoscopy. Since every colorectal cancer
starts as a polyp, detecting all polyps and removing them is crucial. By exactly doing that, colonoscopy reduces
CRC incidence by 80%, however it is an invasive procedure thatmight have unpleasant and, in rare occasions, dan-
gerous side effects. Despite numerous efforts over the past two decades, a non-invasive screeningmethod for the
general population with detection rates for adenomas and CRC similar to that of colonoscopy has not yet been
established. Recent advances in next generation sequencing technologies have yet to be successfully applied to
this problem, because the detection of raremutations has beenhinderedby the systematic biases due to sequenc-
ing context and the base calling quality of NGS.
We present the ﬁrst study that applies the high read accuracy and depth of single molecule, real time, circular
consensus sequencing (SMRT-CCS) to the detection of mutations in stool DNA in order to provide a non-
invasive, sensitive and accurate test for CRC. In stool DNA isolated frompatients diagnosedwith adenocarcinoma,
we are able to detect mutations at frequencies below 0.5% with no false positives. This approach establishes a
foundation for a non-invasive, highly sensitive assay to screen the population for CRC and the early stage adeno-
mas that lead to CRC.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Although the rate of colorectal cancer (CRC) has been declining at
3.0% per year over the past decade, in 2014 there were about 140,000
new cases in the United States making it the thirdmost common cancer
after lung-bronchus and prostate (Cancer Facts and Figures, American
Cancer Society, 2014) and this ﬁgure in North America essentially mir-
rors the latest available worldwide survey (www.globocan.iarc.fr).
A substantial amount of research has been conducted in the past
thirty years to demonstrate that the molecular genetic landscape
of CRC is extremely complex. Single Nucleotide Polymorphisms
(SNPs), Insertion–Deletions (Indels), Microsatellite Instabilities
(MSI), and alteration in methylation patterns can all occur at differ-
ent loci depending on the site of tumor and its stage (Fearon, 2011;r Zurich, ETH Zurich, University
rich, Switzerland.
).
. This is an open access article underThe Cancer Genome Atlas Network, 2012; Tomlinson et al., 2010;
Houlston, 2012).
The molecular mechanisms behind the formation of adenomas and
their progression into CRC were ﬁrst presented 25 years ago in a
model proposed by Fearon and Vogelstein (Fearon and Vogelstein,
1990).
Brieﬂy, early adenomas emerge on the normal epithelium and this
event is associated with mutations in the Adenomatous Polyposis Coli
(APC) or β-catenin (CTNNB1) genes (Morin et al., 1997; Sparks et al.,
1998). Most early adenomas suffer additional mutations in either the
Kirsten Rat Sarcoma (KRAS) or v-rafmurine sarcoma viral oncogene ho-
molog B (BRAF) genes (or other genes of the RTK-RAS pathway), which
lead to the formation of intermediate and larger adenomas (Chan,
2003). It is at this point that chromosomal instabilities (CIN) or deﬁcien-
cy in themismatch repair (MMR) system begin to occur, which leads to
an increasedmutation rate in the neoplastic cells. CIN in colorectal can-
cer is often observed on the long arm of chromosome 18 and it is asso-
ciated with mutations in genes SMAD2 and SMAD4 (Takagi et al., 1996;
Miyaki et al., 1999). These genes represent human homologs ofmothersthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Caenorhabditis elegans. On the other hand, MMR is usually caused by a
decrease in the expression of the MutL-homolog 1 (MLH1) gene on
chromosome 3 through the hyper methylation of the promoter region
(Vilar and Gruber, 2010). MMR induces alteration of microsatellite se-
quences in the tumor cells and increases the overall mutation rate for
all genes, including oncogenes and tumor suppressor genes (Parsons
et al., 1993). Finally, the progression to carcinoma is often accompanied
by themalfunctioning of the cellular tumor antigen TP53, a proteinwith
tumor suppressor activity.
The progression of CRC shows a signiﬁcant acceleration between the
second and the third stage, i.e., upon the onset of CIN orMMR, with sur-
vival rates dropping from 80% to less than 40%, whereas early detection
(stage I) is associatedwith survival rates above 90% (Sameer, 2013). It is
therefore critical to base the screening of the general population on ap-
proaches capable of conﬁdently identifying the ﬁrst, local instances of
adenomas and CRC neoplastic formation.
The methods currently used to test for CRC can be divided into two
general categories: invasive methods such as colonoscopy, and non-
invasive methods that detect biomarkers in stool. Colonoscopy,
i.e., the direct inspection of the colon, is certainly the most accurate ap-
proach as the physician is able to visualize the epithelium and eventual-
ly ascertain the presence of abnormalities on its surface. However it
presents a number of drawbacks. It can still miss a signiﬁcant percent-
age of adenomas, even upon repeated examination and it tends to
have unpleasant, and in rare occasions, dangerous side effects, which
are mostly connected to the preparation that the bowel requires prior
to the procedure (Senore et al., 2011; Lebwohl et al., 2011). Moreover,
this preparation represents an additional step in this screening process
which seems can be sub-optimally performed in a signiﬁcant number of
cases (Lebwohl et al., 2011). Not the least, its invasiveness is the source
of reluctance for a considerable number of individuals, particularly
among certain populations (Ramos et al., 2011; Talaat and Harb,
2013). Despite its lower level of discomfort, since only the rectum and
the lower colon are inspected, similar arguments can be put forward
for ﬂexible sigmoidoscopy (FSG) and computed tomography
colonography (Senore et al., 2011).
Non-invasive tests based on fecal occult blood (FOBTs) are a widely
used screening method. A small sample of stool is self-collected, placed
on a card, and sent to the physician. There are several methods for test-
ing for occult blood in the feces: for instance, fecal immunochemical
testing (FIT) utilizes antibodies to detect human hemoglobin whereas
in guaiac tests (gFOBT) the stool is smeared on a chemically treated
paper which, if blood is present, will change color when absorbing hy-
drogen peroxide. FIT has been shown to perform more effectively than
gFOBT (Sharp et al., 2012), however FOBTs in general are much less ef-
fective in reducing CRC incidence compared to colonoscopy (Moayyedi
and Achkar, 2006), mostly due to their inherent difﬁculties in detecting
early stages polyps, which do not bleed.
Finally, non-invasive testing of stool can be done by interrogating
the genetic material present in a stool sample. The use of DNA testing
for screening is certainly extremely promising, however so far it has
been hindered by its limited sensitivity since, when the presence ofmu-
tatedDNA is to be inferred frombodyﬂuids, the concentration ofmutat-
ed cells becomes extremely low. Being continuously available and easy
to collect and containingmutant DNA from exfoliating adenomas at the
earliest stages of CRC development, stool is the obvious choice for
inspecting potential CRC mutations and it is not surprising that results
based on stool samples are superior to those based on cell free DNA in
blood plasma (Diehl et al., 2008). Early studies using multi-target
panels, based on methylation, mutation and hemoglobin assays report-
ed sensitivities between 70% and 90% for CRC, where the sensitivity
would typically increase with the number of markers included and the
size of the neoplasm (Dong et al., 2001; Ahlquist et al., 2000; Ahlquist
et al., 2012; Traverso et al., 2002a). Recently, a large study of 9989 pa-
tients showed that a multi-panel assay of stool DNA markers coulddetect colorectal cancer with a sensitivity of 92.3%, while 42.4% of pa-
tients with polyps were detected. The false positive rate of the DNA
based test in this study was 13.4% (Imperiale et al., 2014), which
would generate 134 false positives, and consequently 134 unnecessary
follow-ups in the form of colonoscopy, for each 1000 patients screened.
Massive parallel sequencing has been proven successful in identify-
ingmutations from cancerous tissues (Gerecke et al., 2013; Kinde et al.,
2011) and speciﬁc cancer panels, such as the Ion AmpliSeq™Cancer
Hotspot Panel v2 and the TruSeq Amplicon — Cancer Panel (TSACP)
are now available for second generation platforms. However, despite
covering a broad spectrum of genes, their sensitivity is bound at 5%
(Frampton et al., 2013; Fang et al., 2013; http://www.edgebio.com/
ion-ampliseq-ﬁxed-panels-hct-15-colon-carcinoma-cell-line; Singh
et al., 2013), a constraintwhichmakes them ineffective when screening
for CRC using stool DNA.
A recent survey of 224 CRC tumors bywhole exomeDNA sequencing
(The Cancer GenomeAtlas Network, 2012) shows that 93% of all tumors
have mutations in the wnt signaling pathway, 62% have mutations in
the RTK-RAS pathway and 61% have mutations in TP53 signaling. The
fraction of CRC tumors that will not have a mutation in any of these
pathways is then (1–0.93) × (1–0.62) × (1–0.61) = 0.6%, thus the the-
oretical false negative rate due to not looking for the driver mutations
present in a tumor would be 0.6% if all possible mutations were
screened in all of the genes involved in these pathways. The 15
amplicon assays described in this paper will not detect all mutations
in these 3 key pathways, but is designed to detect the maximum num-
berwith a self-imposed limit of 15 amplicons. The number of amplicons
in such an assay, i.e., the genomic spectrum that could be interrogated
by deep sequencing, could certainly be enlarged, however, at the time
of writing, a region of about 5000 nucleotide seemed to be themost ap-
propriate projected trade-off between the size of the region to inspect
and a cost-effective clinical setting, whereby sufﬁcient sequencing
data for a sample could be obtained by employing only on one SMRT
cell.
The rationale behind such an assay is closely reinforced by the fact
that, apart from the aforementioned genes, no equally informative bio-
markers for CRC have been so far reported, as the cases ofmicroRNA and
gut microbiotas witness (Hrašovec and Glavač, 2012; Mazeh et al.,
2013; Zhu et al., 2013; Dejea et al., 2013), where no deﬁnite conclusion
can be drawn regarding an association between biomarkers of that type
and the development of CRC.
In the current study, we present the ﬁrst application of single mole-
cule, real time, circular consensus sequencing (SMRT-CCS) (Travers
et al., 2010) to the detection of mutations associated with CRC using
stool DNA as analyte. The high quality of the raw sequence data pro-
duced by SMRT-CCS allows for a sensitivity of detection in the range
of 0.5–2%, which is required to detect polyps using stool DNA as analyte,
as most of the human DNA in a stool sample from such patients will be
wild type (Traverso et al., 2002b).
2. Materials and methods
2.1. Experimental design
Themain goal of this study is to test the speciﬁcity and sensitivity of
third generation, singlemolecule sequencing in detectingmutated DNA
at concentrations comparable to those observed in stool from exfoliated
cells derived from early stage adenomas.
We performed a series of experiments to detect low frequency CRC
mutations using an assay consisting of ﬁfteen amplicons covering key
regions of the genes most frequently mutated in CRC. The test sequence
includes 8 overlapping amplicons covering codons 840–1581 of the APC
gene, which is twice the size of theMutation Cluster Region (MCR) cov-
ering codons 1210–1581 that has been used previously to detect muta-
tions in stool DNA from patients with polyps (Traverso et al., 2002b).
About 83% of APC mutations in sporadic CRC are found in the MCR,
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(Laurent-Puig et al., 1998). Additional test sequences include exon 3 of
Beta Catenin (CTNNB1) which contains serine and threonine residues
that are mutated in 48% of all CR tumors lacking APC mutations
(Sparks et al., 1998), exon 2 of KRAS containing codons 12 and 13 of
this gene, exon 15 of BRAF which contains the critical codon 600,
often mutated in a number of cancers, and exons 5–8 of the TP53
gene. The amplicons are generated using genomic DNA as template,
pooled at equal molarities and sequenced using the third generation,
single molecule sequencing Paciﬁc Biosciences RS II platform. The
amplicons were optimized to minimize length variability, resulting in
a range of 327–344 bp.
2.2. Simulated stool sample (DLD1/wild type titration)
We simulated a stool sample having 3 mutations in CRC genes
present at the 1.5% level by mixing 97%wild type DNAwith 3% DNA ex-
tracted from theDLD1 CRC cell line, which contains heterozygousmuta-
tions in APC (codon 1416, deletion 1c), KRAS (G13D caused by a g N a
transversion), and TP53 (Ser241Pro caused by a c N t transition). To
compare the performances of SMRT-CCS against second generation se-
quencing technologies, we sequenced the mixed sample, as well as
the wild type, on three platforms: Paciﬁc Biosciences RS II, Illumina
MiSeq and IonTorrent PGM.
For the sequencing on the Pacbio RS II, the SMRT bell libraries were
produced using theDNA Template Prep Kit 2.0 (250 bp— 3Kb) according
to the supplied protocol for blunt ended ligations (Paciﬁc Biosciences p/n
001-540-726).
Paired end, 2 × 250 bp libraries prepared with the The TruSeq DNA
Sample Prep Kit v2 (Illumina, Inc., California, USA) were processed on
the Illumina MiSeq.
Finally, template preparation with the Ion PGM™ Template OT2 400
Kit (Ion Torrent, Life Technologies, USA) preceded sequencing on an Ion
316 (100Mb.p.)micro-chip using the Ion Torrent Personal GenomeMa-
chine (Ion Torrent, Life Technologies, Carlsbad, USA) with the Ion
PGM™ Sequencing 400 Kit for 850 ﬂows.
2.3. CRC tumor tissue
After establishing the workﬂow on DNA derived from cell lines with
knownmutations, we proceeded to analyze DNA from CRC tumor sam-
ples. Genomic DNA extracted from tumor tissue and matched, adjacent
normal tissue (colon) from a 37 y/omale patient diagnosedwith adeno-
carcinoma. The 15 pooled amplicons from the 2DNA sampleswere used
to make 2 PacBio libraries and the libraries were sequenced with one
SMRT cell being used per sample.
2.4. Stool samples from CRC patients
Finally, clinical samples from CRC patients were analyzed. DNA was
ﬁrst isolated from the stool of two sporadic CRC cases, a 90 y/o female
and a 61 y/o male, taken after they were diagnosed with CRC by colo-
noscopy and prior to surgical removal of the tumor (Supplementary
Table 3). After the excision of the cancerous neoplasm, DNA was ex-
tracted from the tissue itself in order to act as a control sample against
which to conﬁrm any mutations found in the DNA isolated from the
stool samples. Only the MCR of the APC gene (codons 1210–1581)
was analyzed for these experiments using 4 overlapping segments of
the APC gene and one SMRT cell was used per library.
2.5. Data analysis
In all cases, CCS reads were generated using the SMRT Analysis 2.1
software. The resulting consensus sequences were aligned to the refer-
ence pools of either 4 or 15 amplicons using the PacBio read-alignment
software Blasr. with the following settings: minMatch = 8,sdpTupleSize = 8, minPctIdentity = 75, bestn = 1, nCandidates = 10,
and maxScore = 500. Following the alignments, consensus calls were
generated by counting at each locus the occurrences of the reference al-
lele and those of the alternative allele in the wild type and the tumor
sample. By doing so, at each position a contingency table was then pro-
duced, leading to a Fisher's exact test to test the hypothesis that the al-
ternative allele frequency in the non-WT sample is signiﬁcantly
different from that of the WT. Based on the assumption that at most
one mutation per codon results in a functional disruption, the resulting
P-values were then Bonferroni-corrected by the number of codons in
each amplicon. In the case of the simulated stool sample sequenced on
the Ion Torrent PGM, data analysis was also streamlined by means of
the variant caller pipeline available on the Torrent Suite, the software
speciﬁcally designed by Life Technologies for the downstream analysis
of sequences generated by Ion Torrent.
3. Results
3.1. Simulated stool sample from wild-type/DLD1 mixture
The purpose of sequencing the mixture of wild-type and 3% DLD1
DNAwas to compare 3 different massively parallel sequencing technol-
ogies with respect to their performances in detecting different types of
mutations at an expected frequency of 1.5%.
When looking at the results, we have obtained the difference be-
tween the Illumina and Ion Torrent platforms and PacBio RS II is evident.
Pacbio RS shows 100% sensitivity and speciﬁcity (Table 1). The three
bona ﬁde mutations known to be present in the DLD1 cell line muta-
tions give strong signals well above background, as the ﬁrst locus out-
side the three known polymorphisms has a P-value thirty times
higher than any of the true mutations.
On the contrary, both the Illumina MiSeq and IonTorrent PGM re-
port a number of false positives and fail to identify one of the bona
ﬁdemutations (Fig. 1). Moreover, when the PGMdata are analyzed di-
rectly on the IonTorrent server through the proprietary aligner, i.e., T-
map (http://mendel.iontorrent.com/ion-docs/Technical-Note-TMAP-
Alignment_9012907.html), and variant caller, no mutations are
found either with stringent or with default settings. This is a further
conﬁrmation that, in the workﬂow of this platform, a mutation with
a frequency of 1.5% is treated as an error and therefore discarded.
3.2. DNA from a CRC tumor
The analysis of the tumor sample from a young patient revealed a
somewhat expected scenario. Two codons were identiﬁed as mutated
(Table 2): a 5-base, germline deletion was detected at codon 1309 of
the APC gene, indicating that this individual was a carrier for the APC
mutation and had familial adenomatous polyposis coli (FAP). The in-
creased frequency of the mutation (above the expected 50% level) in
the tumor tissue is expected due to loss of the wild type allele in that
fraction of the tissue sample that consists of tumor cells. Furthermore
a somatic, missense substitution was identiﬁed at codon 237 of TP53.
Bothmutations are known hotspots associated with CRC and were con-
ﬁrmed by Sanger sequencing (Figs. 2 and 3). The frequency of the TP53
mutation indicates that the cellularity of the tumor sample was approx-
imately 16%, which is in the normal range for CRC biopsies.
This experiment shows that PacBio RS sequencing is capable of iden-
tifying not only mutations in DNA derived from cells cultivated in vitro,
but also from DNA extracted from an in vivo tumor sample where the
nature of the mutations was not known beforehand.
3.3. Stool samples from CRC patients
In order to test the assay on clinically relevant DNA samples, we an-
alyzed paired stool and tumor DNA samples extracted from each of the
two CRC patients. DNA was isolated from stool prior to the surgical
Table 1
Experiment 1: mutations reported based on the sequencing run on the PacBio RS II.
Segment Relative position RA AA Cov. WT AA Freq. WT (%) Cov. DLD1-M AA Freq. DLD1-M (%) P Adj. P
KRAS (*) 214 G A 2095 0 3335 1.29 0 0
APC7 (*) 94 G −C 3346 0.04 4012 0.51 2.30E-05 0.0078
TP53_exon7 (*) 161 C T 2485 0.04 2569 0.70 7.80E-05 0.0284
APC2 26 A +T 3380 0 3753 0.2 0.0021 0.750
Note: (*) True positive. RA: Reference allele. AA: Alternative allele. WT: wild type. DLD1-M: DLD1—mixed sample.
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MCR of the APC genewas analyzed in these experiments. In one patient,
the 5 bp deletion located in the tandem repeat at codon 1309 on theAPC
genewas again encountered. This is not surprising, as this deletion is the
most common APCmutation found in sporadic CRC. The mutation was
detected at a frequency in the stool sample (FS) of 0.57% and conﬁrmed
at a frequency in the cancer sample (FC) of 82.22%. No other mutations
were reported in this patient (Table 3). In the second patient, we iden-
tiﬁed two APCpolymorphisms in theDNA isolated from stool: a rare, but
known mutation (a deletion in a homopolymer stretch) at codon 1491
of the APC gene (FS = 0.37%) and an additional homopolymer insertion
at codon 1556 (FS = 1.32%). In this case, we could conﬁrm the presence
of the deletion at codon 1491 in the cancer sample (FC=19.05%) but no
alterations were detected at codon 1556 (FC = 0.05%) (Table 4).
4. Discussion
The study presented here is the ﬁrst attempt at determining the fea-
sibility of using singlemolecule, third generation sequencing for the de-
tection of CRC driving mutations in stool samples. The ﬁrst step was to
show that mutations present at low levels (1.5%) could be detected
above background using a sequencing-based approach capable of de-
tecting any mutation present in the amplicon. The raw error rate of
the sequence data is critical in this respect because for genes such as
APC, the cancer causing mutations can be found at any position in the
amplicon and often consist of micro insertions and deletions, so that
an error rate as low as 0.7% (the estimated error rate for the Illumina
platform) will produce far too many false positives when scanning a
test sequence of 1116 bp, which is the size of the MCR of the APC
gene. Circular Consensus Sequencing of small amplicons, on the other
hand, generates a highly accurate consensus sequence where the back-
ground is low enough to conﬁdently call mutations at the 1.5% level.
When a stool DNA based screening test is performed for CRC, the
mutations present in a patient sample, if any are indeed present, are un-
known and can be found at many locations in the genes in the assay,
thus the need of deep sequencing for unbiased interrogation of all the
genomic loci. In this respect, the major problem associated with secondFig. 1. Simulated stool sample: comparison of three different sequencing platforms. With
extremely high CCS-reads quality, the results obtained using PacBio are 100% speciﬁc and
sensitive. On the contrary, both IonTorrent PGM and Illumina MiSeq report several false
positive and miss to identify one variant (Supplementary Tables 1 and 2).generation sequencing technologies is the sensitivity of detection. In
particular, the error in calling the nucleotides has systematic bias due
to sequence context, often associated with the PCR ampliﬁcation pro-
cess required for such assays. As a consequence, within a sequencing
run, the error will appear more frequently at the same loci, making
vain any attempt of correction by enlarging the sampling space, i.e. by
increasing the coverage. The error rate of the sequencingmethod there-
by sets an upper limit to the quality of the raw sequences and thus the
inherent sensitivity of the assay.
This type of issue has been already addressed in a couple of recent
works:Lou et al.(2013) generated “circular sequencing” of short reads
prior to the preparation of standard Illumina libraries, with the outcome
of reducing the error rates by two to three orders of magnitude. Chen-
Harris et al.(2013) applied the concept of overlapping read pairs
(ORP) to screen for rare mutants in a viral ecosystem, detecting strains
as rare as 0.1%. When compared to our approach, the former method
has certainly the disadvantage of an extra wet-lab step prior to the
start of the standard protocol, which translates into additional time con-
sumption and cost. In particular, the error rates are yes improved, but
still, at a reported 7.6 × 10−6, they remain at most comparable to
those reached by the CCS algorithm (Table 1). As for the latter, the re-
sults are very promising, but in principle ORP only take advantage of
two copies of the same molecule (the forward and the reverse read).
With PacBio RS II, sequencing continues as long as the polymerase is ac-
tive and generates raw reads with an average length of 8000 nucleo-
tides, scanning the same molecules many times over. Moreover, the
distribution of base calling error is random (Carneiro et al., 2012). Con-
sequently targeted amplicons, whose length is usually in the range of
hundreds of bases, are each sequencedmany times and any random se-
quencing error will be canceled out when consensus sequence is gener-
ated (Carneiro et al., 2012).
In the analysis of the simulated stool sample, the differences in the
results between PacBio RS and the two 2nd generation platforms,
Illumina MiSeq and IonTorrent PGM, are striking. PacBio RS shows
100% speciﬁcity and sensitivity. Remarkably, the fraction of the mutant
allele in the APC deletion and in the TP53 substitution is smaller than
targeted (0.5% and 0.75%, respectively) but the total absence of error
in the wild type ensures that the mutations are still signiﬁcant, even
after Bonferroni correction (Table 1).
On the contrary, both theMiSeq and PGM are unable to identify one
mutation. In the case of theMiSeq, despite a sequencing run beyond theTable 2
Experiment 2: mutations found in the DNA samples extracted from 37 y/o patient
diagnosed with adenocarcinoma.
Germline mutation Somatic mutation
Gene APC TP53
Codon 1309 237
Reference allele T G
Alternative allele (AA) -AAAAG A
Coverage in the wild type (WT) 2022 1728
AA frequency in the WT 48.22% 0.00%
Coverage in the patient sample 1271 872
AA frequency in the patient sample 68.61% 12.96%
P-value 0 1.45E-56
Adjusted P-value 0 4.98E-54
Fig. 2. Conﬁrmation by Sanger sequencing of the germline, 5 bp deletion in the tumor sample from a 37 y/o patient diagnosed with adenocarcinoma. This mutation represents the most fre-
quently mutated codon in the APC gene. The DNA samples extracted form both the tumor and the healthy, adjacent tissues were sequenced on one SMRT cell. By means of third generation
sequencing, the deletion was identiﬁed with frequencies of 48.22% and 68.61% in the normal (A) and the tumor (B) tissues, respectively (P b 1e-256 in both cases, Fisher's exact test).
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induced, sequence context systematic bias has likely occurred. This is
augmented by the observation that the alternative nucleotide at relative
position 161 of TP53_exon7 is observed as being adenine instead of thy-
mine in both the wild type and the mutant samples (Supplementary
Table 1).
The lower overall quality of the PGM (Supplementary Fig. S2) in-
stead generates too much background noise in the wild-type which
masks the correct alternative observation of adenine as mutated allele
in the KRAS gene. Furthermore, the average sequencing quality of the
second generation technologies, which is two to three orders of magni-
tude lower than the PacBio CCS, generates a large amount of false posi-
tiveswhen a direct case/control Fisher's test is adopted (Supplementary
Tables 1 and 2). When such false positives are present in a test for CRC
they would result in a substantial number of unnecessary follow-up co-
lonoscopies which would increase costs and cause emotional stress for
the patients. The relatively high raw error rate for second generation se-
quencing in its present form allows it to be used for detectingmutations
in tumor tissuewhere themutant allele frequency is often above 5%, butmakes them inadequate to identify low frequency mutations in DNA
isolated from stool.
As expected, PacBio RS II was able to detect driver mutations in
DNA derived from a CRC tumor in the case of the 37 year old patient.
However, in order to test the feasibility of applying our approach for
an unmet clinical need, we have isolated DNA from the stool of two
patients diagnosed with adenocarcinoma and from the tumor tissues
after surgery. In both patients, we identiﬁed a known CRC associated
mutation which was then conﬁrmed in the tumor DNA. At 0.37% and
0.57%, the frequencies of mutated DNA in the stool sample were low;
however, the absence of sequencing errors at this level in the wild
type allowed those observations to be conﬁdently reported as signif-
icantly different from the wild type even after a stringent Bonferroni
correction.
In one stool sample, we also identiﬁed a second mutation at codon
1556 of the APC gene. This codon is the eighth most frequently mutated
codon in CRC and this mutation is extremely signiﬁcant in our stool
sample (P = 2.72e-26, PBonf = 9.35e-24). Therefore, despite the fact
that this polymorphism was not observed in the DNA from the tumor
Fig. 3. Conﬁrmation by Sanger sequencing of the somatic point substitution in the tumor sample from a 37 y/o patient diagnosedwith adenocarcinoma. Thismutation represents the third
most frequently mutated codon in the TP53 gene. Themutation in the tumor sample (B) is a heterozygous substitution which occurs at a frequency of 15.96% (highlighted in purple). De-
spite this rather low cellularity, the total absence of backgroundnoise allows for an easy detection of the greenA signal in the Sanger sequencing track,which is instead clearly absent in the
healthy tissue (A).
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positives reported, not even at lower frequencies. We believe that this
mutation might either come from a secondary neoplastic formation,
which perhaps was not fully developed yet at the time of theTable 3
Experiment 3: mutations found in the DNA samples extracted from patient 1.
Tumor Stool
Gene APC6 APC6
Codon 1309 1309
Reference allele T T
Alternative allele (AA) -AAAAG -AAAAG
Coverage in the wild type (WT) 4658 4658
AA frequency in the WT (%) 0.00 0.00
Coverage in the patient sample 3897 4550
AA frequency in the patient sample (%) 82.22 0.57
P-value 0 1.22E-08
Adjusted P-value 0 3.66E-06colonoscopy and therefore was not resected; alternatively, and most
probably, is the result of tumor cellular polyclonality, whereby the iso-
lated DNA from the resected tumor sample captured only one cellular
sub-population.Table 4
Experiment 3: mutations found in the DNA samples extracted from patient 2.
Tumor Stool
Gene APC APC APC
Codon 1491 1491 1556
Reference allele A A G
Alternative allele (AA) −T −T +A
Coverage in the wild type (WT) 7372 7372 7359
AA frequency in the WT (%) 0.00 0.00 0.04
Coverage in the patient sample 8005 8005 7984
AA frequency in the patient sample (%) 19.05 0.37 1.32
P-value 0 3.04E-09 2.72E-26
Adjusted P-value 0 3.43E-07 8.16E-24
38 G. Russo et al. / Applied & Translational Genomics 7 (2015) 32–39In conclusion, the use of third generation, single molecule sequenc-
ingwith PacBio RS technology allows for the identiﬁcation of mutations
at 0.5% frequency, and as this is a sequencing method, any mutation
within the amplicon can be detected. As most APC mutations detected
in stool DNA frompatientswith polyps present in at least in this amount
(Traverso et al., 2002b), the potential exists to screen non-symptomatic
patients for polyps using this approach. In this respect, this type of
screening could result in a much earlier identiﬁcation of neoplastic for-
mation than currently non-invasive tests such as FOBTs. Althoughwith-
in FOBTs the antibodies-based detection (FIT) has proven to be superior
to other tests (Sharp et al., 2012), the fact that polyps and early adeno-
mas do not bleed de facto limits the scope of FOBTs to already cancerous
lesions, which often appear only in stage III of the development of the
malignancy, when survival rated have already dropped signiﬁcantly
(Sameer, 2013).
Despite these encouraging results, we clearly need to underline that
the current study only represents a pilot experiments, and a large scale,
cohort studywill be certainly required to eventually validate our ﬁnding
in a deﬁnitive manner, as well as to leverage sufﬁcient statistical power
to infer meaningful false positive and miss rates. Moreover, a larger
sample should ideally include CRC lesions at different stages, so to pro-
duce an even ﬁner granularity in the results.
With respect to cost, PacBio RS II is currently generating enough
throughput to sequence at least one sample on one SMRT cell. At the
time of writing, the full cost for sequencing one SMRT cell, i.e., from
sample delivery to data generation, is around $700 to $1000, depending
on the provider and whether the customer is a research or a for-proﬁt
institution. This ﬁgure does not include the cost to isolate DNA from
stool and amplify the genes of interest, an expense that gravitates
(e.g., QIAmpmini stool kit and Haloplex custom) around $100 per sam-
ples. Therefore, even assuming that further advances in research will
not reduce the current cost per sample for preparing and sequencing
an assay like the one we described, the current price is already compet-
itive with that of a colonoscopy, at least in the USA, where it already
exceeds $1000 for Medicare patients (Pyenson et al., 2014). Moreover,
the total cost of a colonoscopy can vary enormously, reaching peaks of
$9000 in certain States for commercial payers, because a lot of factors
can play a role in rising the price. For example, outpatients in hospitals
will pay more than patients in doctor's ofﬁces, and general anesthesia
represents another signiﬁcant expense (International Federation of
Health Plans, 2012). Instead, a genetic screening test is immune
to all this, as its cost can be easily broken down into simple, stable
components.
With respect to the cost of other sequencing technology, Illumine
MiSeq might have an edge at this regard, given the larger throughput
generated, however the key aspect of sensitivity discussed previously
would still hold. Certainly a deep, large scale cost analysis, expanding
also outside the US health system (which is notably expensive), will
be required to provide a more comprehensive picture.
Finally, a few words about the perspective of introducing such a
screening procedure in the public health sector: given the investment
required to purchase and operate at capacity a Paciﬁc Biosciences in-
strument, a centralized approached seems favorable and a strategic
planning would be needed to ensure a sufﬁciently capillary network
of centers able to offer such a sequencing service. As far as turnaround
time is concerned, an optimized, streamlined version of our current
workﬂow could be reasonably completed in 36 h for a full run, which
would scan at least 16 samples. This is, per sample, faster than a colo-
noscopy (which involves also a preparatory day), however, even by in-
creasing the instrument capacity by means of poolingmultiple samples
in one SMRT cell, the number of instrument required to keep up with
the 14 million procedures performed yearly in the USA alone would
be too large to envisage this sequencing approach to quickly become
mainstream.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.atg.2015.08.006.Authors' contributions
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